Loading organizations...
§ Private Profile · 9 Appold St, London, United Kingdom
Lifebit is a technology company.
Lifebit develops a data intelligence platform that unifies and analyzes genomic and biomedical data for precision medicine. The platform facilitates secure, in-place access and advanced analytics over distributed datasets without requiring their movement. Key offerings include a Trusted Research Environment, a Trusted Data Lakehouse, and a Trusted Data Marketplace, which collectively enable efficient data management, utilization, and insight generation.
The company was founded in 2017 by Dr. Maria Chatzou Dunford and Dr. Pablo Prieto Barja. Their insight stemmed from the critical need to democratize access to vast, disparate omics data securely and efficiently, allowing researchers to derive meaningful scientific discoveries. Dr. Chatzou Dunford, as CEO, and Dr. Prieto Barja leveraged their backgrounds in life sciences and bioinformatics to build this federated data solution.
Lifebit serves a diverse clientele including government agencies, commercial pharmaceutical companies, health nonprofits, health systems, and data providers. Its long-term vision is to accelerate drug discovery, therapeutic development, and real-time surveillance by enabling scalable, secure access to multi-omic data. The company focuses on transforming complex data into actionable insights, ultimately advancing clinical actions and scientific research.
Lifebit has raised $70.9M across 3 funding rounds.
Lifebit has raised $70.9M in total across 3 funding rounds.
Lifebit has raised $70.9M across 3 funding rounds. Most recently, it raised $60.0M Series B in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2021 | $60M Series B | Tiger Global Management, JIM Rowley, Mark Mastrov | AngelList, Beenext, DST Global, Fundamentum, Matrix Partners India, Kunal Shah, Beacon Capital, Eurazeo, Pentech Ventures | Announced |
| Apr 1, 2020 | $8M Series A | Antoine Zins | Eurazeo, Hugues DE Braucourt, Beacon Capital, Connect Ventures, Pentech Ventures | Announced |
| Jul 19, 2018 | $2.9M Seed | Connect Ventures, Sandy McKinnon | Beacon Capital, Tiny VC | Announced |
Lifebit has raised $70.9M in total across 3 funding rounds.
Lifebit's investors include Tiger Global Management, Jim Rowley, Mark Mastrov, AngelList, BEENEXT, DST Global, Fundamentum, Matrix Partners India, Kunal Shah, Beacon Capital, Eurazeo, Pentech Ventures.
Lifebit is a precision medicine software company headquartered in London, UK, that builds enterprise data platforms for organizations handling sensitive genomic and biomedical datasets.[1][2] Its core products include Lifebit CloudOS, a federated solution for FAIR omics and biomedical analysis that enables faster, cheaper, and secure scaling in existing data environments, and Lifebit AI-Engine, which uses deep learning to analyze drug responses, repurpose drugs, validate targets, and optimize vaccines.[1][3] Lifebit serves leading life sciences organizations, pharmaceutical companies, and healthcare providers like Flatiron Health, addressing the challenge of accessing and analyzing siloed biomedical data without risky data movement.[1][2] The platform supports secure federated analysis, data transformation to standards like OMOP, trusted research environments (TREs), and AI-driven cohort building, with growth evidenced by partnerships expanding into Japan for real-world oncology data and access to 270M+ harmonized datasets.[1][3]
Lifebit was founded to tackle the growing challenge of utilizing vast amounts of siloed biomedical data generated in precision medicine, where data access has become a major barrier to curing diseases.[2] Led by Dr. Maria Chatzou Dunford, Chief Executive Officer, the company emerged from expertise in bioinformatics, clinical research, and engineering, developing patented technology for in-situ federated analysis on distributed datasets.[2] Early focus centered on creating secure platforms for genomics and health data, evolving into a full ecosystem with CloudOS and AI-Engine, backed by investors and memberships in key industry groups.[2] Pivotal moments include multi-year partnerships like with Flatiron Health, now extending to Japan for cancer care research using TRE technology on real-world data.[1]
Lifebit rides the precision medicine and federated learning wave, where explosive growth in genomic, omics, and real-world health data (e.g., from EHRs like Epic) outpaces traditional centralized analysis due to privacy regulations and silos.[2][3][4] Timing is ideal amid rising demand for secure, scalable data platforms post-GDPR/HIPAA evolutions and AI advancements in drug discovery, enabling global collaborations without data centralization risks.[1][5] Market forces like biopharma's push for faster target validation and multi-ancestry genomics favor Lifebit's in-situ federation and AI, as seen in oncology RWD partnerships.[1][3] It influences the ecosystem by standardizing TREs, OMOP transformations, and marketplaces, democratizing access for researchers and accelerating discoveries in cancer care and beyond.[2][4]
Lifebit is poised to dominate federated biomedical data platforms as AI agents and multi-omics integration become standard in precision medicine.[3] Next steps likely include expanding TRE marketplaces globally, deeper EHR federations, and AI enhancements for real-time clinical trials, fueled by partnerships like Flatiron in Japan.[1] Trends like regulatory pushes for data interoperability and AI-driven drug repurposing will amplify its momentum, potentially evolving it into a central hub for 1B+ global health datasets. This positions Lifebit as a key enabler in overcoming data silos, directly advancing its mission to make biomedical data a tool for curing diseases rather than an obstacle.[2]